DLL3 Targeting Chimeric Antigen Receptors and Binding Agents

EPO published patent application EP3930744A1 for DLL3 targeting chimeric antigen receptors and binding agents, filed jointly by Allogene Therapeutics and Pfizer. The application claims compositions and methods for targeting DLL3 (Delta-like ligand 3) using chimeric antigen receptors and associated binding agents for therapeutic applications, particularly in cancer treatment. The published application is classified under A61K 39/00, A61P 35/00, and C07K 16/28.\n\nCompetitors developing DLL3-targeted therapies or CAR-based treatments should review this publication to assess potential freedom-to-operate implications. The broad designation across 31 European states means this publication creates prior art throughout the EPO contracting states. Pharmaceutical and biotechnology companies in the CAR-T and targeted oncology space should monitor the prosecution of this application.